Literature DB >> 30354407

Collagen Biomarkers and Incidence of New Onset of Atrial Fibrillation in Subjects With No Overt Cardiovascular Disease at Baseline: The Multi-Ethnic Study of Atherosclerosis.

Daniel A Duprez1, Susan R Heckbert2, Alvaro Alonso3, Myron D Gross4, Joachim H Ix5, Jorge R Kizer6, Russell P Tracy7, Richard Kronmal8, David R Jacobs9.   

Abstract

BACKGROUND: Atrial fibrosis is a hallmark of structural remodeling in atrial fibrillation (AF). Plasma procollagen type III N-terminal propeptide (PIIINP) reflects collagen synthesis and degradation while collagen type I carboxy-terminal telopeptide (ICTP) reflects collagen degradation. We aimed to study baseline plasma PIIINP and ICTP and their associations with incident AF in participants initially free of overt cardiovascular disease.
METHODS: In a stratified sample of the Multi-Ethnic Study of Atherosclerosis, initially aged 45-84 years, 3071 participants had both PIIINP and ICTP measured at baseline. Incident AF in 10-year follow-up was based on a hospital International Classification of Diseases code for AF or atrial flutter, in- or outpatient Medicare claims through 2011 (primarily in those aged 65-84 years), or ECG 10 years after baseline (n=357). The associations of PIIINP and ICTP with incident AF were estimated using Poisson regression with follow-up time offset.
RESULTS: Baseline PIIINP (5.50±1.55 µg/L) and ICTP (mean±SD, 3.41±1.37 µg/L) were positively related (both P<0.0001) to incident AF in a model adjusting for age, race/ethnicity, and sex, with an apparent threshold (relative incidence density 2.81 [1.94-4.08] for PIIINP ≥8.5 µg/L [3.5% of the sample] and 3.46 [2.36-5.07] for ICTP ≥7 µg/L [1.7% of the sample]). Findings were attenuated but remained statistically significant after further adjustment for systolic blood pressure, height, body mass index, smoking, and renal function. Additional adjustment for other risk factors and biomarkers of inflammation did not alter conclusions.
CONCLUSIONS: Plasma collagen biomarkers, particularly at elevated levels, were associated with excess risk for AF.

Entities:  

Keywords:  atrial fibrillation; body mass index; cohort studies; collagen; incidence

Mesh:

Substances:

Year:  2018        PMID: 30354407     DOI: 10.1161/CIRCEP.118.006557

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  7 in total

Review 1.  The Atrium in Atrial Fibrillation - A Clinical Review on How to Manage Atrial Fibrotic Substrates.

Authors:  Pedro Silva Cunha; Sérgio Laranjo; Jordi Heijman; Mário Martins Oliveira
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  CD5L, Macrophage Apoptosis Inhibitor, Was Identified in Epicardial Fat-Secretome and Regulated by Isoproterenol From Patients With Heart Failure.

Authors:  Rosa M Agra-Bermejo; Carla Cacho-Antonio; Adriana Rozados-Luis; Marinela Couselo-Seijas; Angel L Fernandez; J M Martinez-Cereijo; S B Bravo; Jose R Gonzalez-Juanatey; Sonia Eiras
Journal:  Front Physiol       Date:  2020-06-30       Impact factor: 4.566

3.  The association of novel inflammatory marker GlycA and incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Sunyoung Jang; Oluseye Ogunmoroti; Di Zhao; Oluwaseun E Fashanu; Martin Tibuakuu; Eve-Marie Benson; Faye Norby; James D Otvos; Susan R Heckbert; Moyses Szklo; Erin D Michos
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

4.  Cardiovascular magnetic resonance-determined left ventricular myocardium impairment is associated with C-reactive protein and ST2 in patients with paroxysmal atrial fibrillation.

Authors:  Lei Zhao; Songnan Li; Chen Zhang; Jie Tian; Aijia Lu; Rong Bai; Jing An; Andreas Greiser; Jie Huang; Xiaohai Ma
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-22       Impact factor: 5.364

Review 5.  Research Progress of Myocardial Fibrosis and Atrial Fibrillation.

Authors:  Guangling Li; Jing Yang; Demei Zhang; Xiaomei Wang; Jingjing Han; Xueya Guo
Journal:  Front Cardiovasc Med       Date:  2022-07-25

6.  Galectin-3, N-terminal Propeptides of Type I and III Procollagen in Patients with Atrial Fibrillation and Metabolic Syndrome.

Authors:  Valery A Ionin; Elena I Baranova; Ekaterina L Zaslavskaya; Elena Yu Petrishcheva; Aleksandr N Morozov; Evgeny V Shlyakhto
Journal:  Int J Mol Sci       Date:  2020-08-08       Impact factor: 5.923

7.  Atrial Remodeling in Atrial Fibrillation. Comorbidities and Markers of Disease Progression Predict Catheter Ablation Outcome.

Authors:  Judit Szilágyi; László Sághy
Journal:  Curr Cardiol Rev       Date:  2021
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.